Parkhurst et al. proposed a strategy, which screen upregulates CD137 after antigen-specific stimulation to enrich tumor-reactive T cells and isolate TCRs, and then introduce it into less-differentiated PBLs for reinfusion therapy [59]. Here, TNFRSF9 is linked to neoplasm.